Literature DB >> 25729477

Micro RNAs in the development of non-alcoholic fatty liver disease.

Glenn S Gerhard1, Johanna K DiStefano1.   

Abstract

Nonalcoholic fatty liver disease or nonalcoholic fatty liver disease (NAFLD) refers to a group of disorders that arise from the accrual of fat in hepatocytes. Although various factors have been associated with the development of NAFLD, including genetic predisposition and environmental exposures, little is known about the underlying pathogenesis of the disease. Research efforts are ongoing to identify biological targets and signaling pathways that mediate NAFLD. Emerging evidence has implicated a role for micro RNAs (miRNAs), short single-stranded molecules that regulate gene expression either transcriptionally, through targeting of promoter regions, or post-transcriptionally, by blocking translation or promoting cleavage of specific target mRNAs. Several miRNAs have been associated with NAFLD, although our understanding of the biology underlying their role is still emerging. The goal of this review is to present an overview of the current state of knowledge of miRNAs involved in the development of NAFLD across a range of in vitro and in vivo models, including miRNAs that contribute to pathological mechanisms related to fatty liver in humans. Much less is known about the specific targets of miRNAs in cells, nor the molecular mechanisms involved in the development and progression NAFLD and related outcomes. More recently, the identification and validation of miRNA signatures in serum may facilitate the development of improved methods for diagnosis and clinical monitoring of disease progression.

Entities:  

Keywords:  Cell culture; Human; MiRNA; Mouse; Nonalcoholic fatty liver disease

Year:  2015        PMID: 25729477      PMCID: PMC4342604          DOI: 10.4254/wjh.v7.i2.226

Source DB:  PubMed          Journal:  World J Hepatol


  38 in total

1.  Identification of MicroRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening.

Authors:  Ross Whittaker; Patricia A Loy; Eugene Sisman; Eigo Suyama; Pedro Aza-Blanc; Randall S Ingermanson; Jeffrey H Price; Patrick M McDonough
Journal:  J Biomol Screen       Date:  2010-07-16

Review 2.  Zebrafish: gaining popularity in lipid research.

Authors:  Maarit Hölttä-Vuori; Veijo T V Salo; Lena Nyberg; Christian Brackmann; Annika Enejder; Pertti Panula; Elina Ikonen
Journal:  Biochem J       Date:  2010-07-15       Impact factor: 3.857

3.  Difference in expression of hepatic microRNAs miR-29c, miR-34a, miR-155, and miR-200b is associated with strain-specific susceptibility to dietary nonalcoholic steatohepatitis in mice.

Authors:  Igor P Pogribny; Athena Starlard-Davenport; Volodymyr P Tryndyak; Tao Han; Sharon A Ross; Ivan Rusyn; Frederick A Beland
Journal:  Lab Invest       Date:  2010-06-14       Impact factor: 5.662

Review 4.  The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis.

Authors:  Mangesh R Pagadala; Arthur J McCullough
Journal:  Clin Liver Dis       Date:  2012-06-27       Impact factor: 6.126

5.  Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver.

Authors:  Shu-Hao Hsu; Bo Wang; Janaiah Kota; Jianhua Yu; Stefan Costinean; Huban Kutay; Lianbo Yu; Shoumei Bai; Krista La Perle; Raghu R Chivukula; Hsiaoyin Mao; Min Wei; K Reed Clark; Jerry R Mendell; Michael A Caligiuri; Samson T Jacob; Joshua T Mendell; Kalpana Ghoshal
Journal:  J Clin Invest       Date:  2012-07-23       Impact factor: 14.808

6.  Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression.

Authors:  Chikako Shibata; Takahiro Kishikawa; Motoyuki Otsuka; Motoko Ohno; Takeshi Yoshikawa; Akemi Takata; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Biochem Biophys Res Commun       Date:  2013-07-24       Impact factor: 3.575

7.  Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline- and folate-deficient diet.

Authors:  Volodymyr P Tryndyak; John R Latendresse; Beverly Montgomery; Sharon A Ross; Frederick A Beland; Ivan Rusyn; Igor P Pogribny
Journal:  Toxicol Appl Pharmacol       Date:  2012-04-24       Impact factor: 4.219

8.  The effects of miR-467b on lipoprotein lipase (LPL) expression, pro-inflammatory cytokine, lipid levels and atherosclerotic lesions in apolipoprotein E knockout mice.

Authors:  Guo-Ping Tian; Yan-Yan Tang; Ping-Ping He; Yun-Cheng Lv; Xin-Pin Ouyang; Guo-Jun Zhao; Shi-Lin Tang; Jian-Feng Wu; Jia-Lin Wang; Juan Peng; Min Zhang; Yuan Li; Francisco S Cayabyab; Xi-Long Zheng; Da-Wei Zhang; Wei-Dong Yin; Chao-Ke Tang
Journal:  Biochem Biophys Res Commun       Date:  2013-12-02       Impact factor: 3.575

9.  Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease.

Authors:  Silvia Cermelli; Anna Ruggieri; Jorge A Marrero; George N Ioannou; Laura Beretta
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

10.  Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation.

Authors:  Takeshi Yoshikawa; Akemi Takata; Motoyuki Otsuka; Takahiro Kishikawa; Kentaro Kojima; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Sci Rep       Date:  2012-09-06       Impact factor: 4.379

View more
  14 in total

Review 1.  Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date.

Authors:  Somaya Albhaisi; Arun J Sanyal
Journal:  Pharmaceut Med       Date:  2019-12

Review 2.  New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.

Authors:  Mary Barbara; Andrea Scott; Naim Alkhouri
Journal:  Hepatobiliary Surg Nutr       Date:  2018-10       Impact factor: 7.293

Review 3.  Circulating microRNAs in nonalcoholic fatty liver disease.

Authors:  Johanna K DiStefano; Glenn S Gerhard
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-15       Impact factor: 3.869

4.  Activation of the SIRT1/p66shc antiapoptosis pathway via carnosic acid-induced inhibition of miR-34a protects rats against nonalcoholic fatty liver disease.

Authors:  W Shan; L Gao; W Zeng; Y Hu; G Wang; M Li; J Zhou; X Ma; X Tian; J Yao
Journal:  Cell Death Dis       Date:  2015-07-23       Impact factor: 8.469

Review 5.  New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD).

Authors:  Xu Zhang; Xuetao Ji; Qian Wang; John Zhong Li
Journal:  Protein Cell       Date:  2017-06-22       Impact factor: 14.870

6.  Effect of Chronic Western Diets on Non-Alcoholic Fatty Liver of Male Mice Modifying the PPAR-γ Pathway via miR-27b-5p Regulation.

Authors:  Jian Zhang; Catherine A Powell; Matthew K Kay; Ravi Sonkar; Sunitha Meruvu; Mahua Choudhury
Journal:  Int J Mol Sci       Date:  2021-02-12       Impact factor: 5.923

7.  mRNA-miRNA-lncRNA Regulatory Network in Nonalcoholic Fatty Liver Disease.

Authors:  Marwa Matboli; Shaimaa H Gadallah; Wafaa M Rashed; Amany Helmy Hasanin; Nada Essawy; Hala M Ghanem; Sanaa Eissa
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

Review 8.  Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.

Authors:  Antonella Borrelli; Patrizia Bonelli; Franca Maria Tuccillo; Ira D Goldfine; Joseph L Evans; Franco Maria Buonaguro; Aldo Mancini
Journal:  Redox Biol       Date:  2018-02-03       Impact factor: 11.799

9.  Targeting a phospho-STAT3-miRNAs pathway improves vesicular hepatic steatosis in an in vitro and in vivo model.

Authors:  Laura Belloni; Silvia Di Cocco; Francesca Guerrieri; Abigail D G Nunn; Silvia Piconese; Debora Salerno; Barbara Testoni; Claudio Pulito; Federica Mori; Matteo Pallocca; Andrea Sacconi; Elisa Vivoli; Fabio Marra; Sabrina Strano; Giovanni Blandino; Massimo Levrero; Natalia Pediconi
Journal:  Sci Rep       Date:  2018-09-11       Impact factor: 4.379

10.  Serum Micro-RNA-122 Level as a Simple Noninvasive Marker of MAFLD Severity.

Authors:  Mona A Hegazy; Ibrahim Abd ALgwad; Soheir Abuel Fadl; Mohamed Sayed Hassan; Laila Ahmed Rashed; Maha A Hussein
Journal:  Diabetes Metab Syndr Obes       Date:  2021-05-19       Impact factor: 3.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.